Compare UTZ & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTZ | VOR |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 681.8M | 767.4M |
| IPO Year | 2018 | 2021 |
| Metric | UTZ | VOR |
|---|---|---|
| Price | $7.76 | $13.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | $11.93 | ★ $45.33 |
| AVG Volume (30 Days) | ★ 1.7M | 1.3M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $1,438,800,000.00 | N/A |
| Revenue This Year | $5.16 | N/A |
| Revenue Next Year | $1.45 | N/A |
| P/E Ratio | $756.50 | ★ N/A |
| Revenue Growth | ★ 2.09 | N/A |
| 52 Week Low | $7.12 | $0.13 |
| 52 Week High | $14.67 | $49.95 |
| Indicator | UTZ | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 42.32 |
| Support Level | $7.22 | $11.38 |
| Resistance Level | $8.01 | $16.87 |
| Average True Range (ATR) | 0.28 | 1.23 |
| MACD | 0.05 | -0.25 |
| Stochastic Oscillator | 65.03 | 3.32 |
Utz Brands Inc is a manufacturer of branded salty snacks based in the United States. It produces various salty snack foods, including potato chips, tortilla chips, pretzels, cheese snacks, party mixes, pork skins, ready-to-eat popcorn, and other snacks, which include salsa and dips. These products are offered through its flagship brands like Utz, On The Border, Zapp's, and Boulder Canyon, along with other brands, including Golden Flake, Miguelito's, Hawaiian, Bachman, Tim's Cascade, Dirty Potato Chips, TGI Fridays, and Vitner's. The company's products are packaged in a variety of different sizes and configurations, ranging from individual packages to shareable bulk containers. It also sells certain third-party branded products through its distribution network.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.